Advertisement

Impatto della 18F-DOPA PET/CT nella gestione clinica del carcinoma midollare della tiroide

  • Gianluca Bottoni
  • Michela Massollo
  • Arnoldo Piccardo
Rassegna
  • 5 Downloads

Sommario

L’ecografia del collo è l’esame morfologico di immagine di primo livello per identificare la recidiva del carcinoma midollare della tiroide (CMT). In assenza di criteri ecografici dirimenti e in presenza di valori elevati di calcitonina può essere necessario introdurre una diagnostica per immagini di secondo livello in grado di esplorare con elevata sensibilità la regione cervicale e il corpo intero. Scopo principale di questo articolo è quello di riportare, nell’attuale contesto diagnostico, il ruolo della 18F-DOPA PET/CT (Total-Body) in caso di sospetta persistenza-recidiva di CMT.

Parole chiave

Carcinoma midollare della tiroide PET/TC 18F-FDG 18F-DOPA 

Notes

Conflitto di interesse

Gli autori Gianluca Bottoni, Michela Massollo e Arnoldo Piccardo dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_495_MOESM1_ESM.doc (37 kb)
(DOC 37 kB)
40619_2018_495_MOESM2_ESM.doc (36 kb)
(DOC 37 kB)

Bibliografia

  1. 1.
    Wells SA Jr, Asa SL, Dralle H et al. (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610 CrossRefGoogle Scholar
  2. 2.
    Kauhanen S, Schalin-Jantti C, Seppanen M et al. (2011) Complementary roles of 18F-DOPA PET/CT and 18FFDG PET/CT in medullary thyroid cancer. J Nucl Med 52:1855–1863 CrossRefGoogle Scholar
  3. 3.
    Treglia G, Piccardo A, Giovanella L (2017) Radionuclide imaging of medullary thyroid carcinoma. In: Pacak K, Taïeb D (eds) Diagnostic and therapeutic nuclear medicine for neuroendocrine tumors. Contemporary Endocrinology. Humana Press, Cham.  https://doi.org/10.1007/978-3-319 Google Scholar
  4. 4.
    Skoura E, Datseris IE, Rondogianni P et al. (2012) Correlation between calcitonin levels and [18F]FDGPET/CT in the detection of recurrence in patients with sporadic and hereditary medullary thyroid cancer. ISRN Endocrinol 2012:375231 CrossRefGoogle Scholar
  5. 5.
    Treglia G, Villani MF, Giordano A, Ruffini V (2012) Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42:535–545 CrossRefGoogle Scholar
  6. 6.
    Taïeb D, Timmers HJ, Hindié E et al. the European Association of Nuclear Medicine (2012) EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1977–1979 CrossRefGoogle Scholar
  7. 7.
    Treglia G, Cocciolillo F, Di Nardo F et al. (2012) Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol 19:1290–1299 CrossRefGoogle Scholar
  8. 8.
    Luster M, Karges W, Zeich K et al. (2010) Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20(5):527–533 CrossRefGoogle Scholar
  9. 9.
    Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R et al. (2017) Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging 44:2004–2013 CrossRefGoogle Scholar
  10. 10.
    Verbeek HH, Plukker JT, Koopmans KP et al. (2012) Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 53:1863–1871 CrossRefGoogle Scholar
  11. 11.
    Werner RA, Schmid JS, Higuchi T et al. (2018) Predictive value of (18)F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med 59(5):756–761 CrossRefGoogle Scholar
  12. 12.
    Rasul S, Hartenbach S, Rebhan K et al. (2018) [(18)F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging.  https://doi.org/10.1007/s00259-018-4045-9 Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Gianluca Bottoni
    • 1
  • Michela Massollo
    • 1
  • Arnoldo Piccardo
    • 1
  1. 1.Dipartimento di Medicina NucleareOspedali Galliera di GenovaGenovaItalia

Personalised recommendations